Pediatric Pleural Effusion Treatment & Management
- Author: Dagnachew (Dagne) Assefa, MD, FAAP, FCCP; Chief Editor: Michael R Bye, MD more...
Noninflammatory pleural effusions (such as transudates) are managed by treating the underlying cause and by supportive care of any functional disturbances. Treatment of tuberculous pleural effusion (TPE) is similar to that of pulmonary tuberculosis.
Treatment goals in empyema include sterilization of pleural fluid, reexpansion of the lung, and restoration of normal lung function. Prospective studies in pediatric empyema are lacking. Hence, the management of empyema in children remains controversial; given the limited evidence, no consensus has been reached on the role of medical versus surgical management.
Parapneumonic effusion usually progresses through different stages over time, including exudative, fibrinopurulent, and organizational stages. Therefore, different management strategies may be appropriate at different stages.
Currently available treatment options for pediatric parapneumonic effusion and empyema include antibiotics alone or in combination with thoracocentesis, chest tube drainage with or without instillation of fibrinolytic agents, and surgery (video-assisted thoracoscopic surgery or open thoracotomy with decortication). In practice, the care that a child with empyema receives depends on local practice, which is largely determined by the availability of medical personnel and their preferences.
Consultations may include the following:
Pediatric infectious disease specialist
In the earlier stages of parapneumonic effusion formation (mild symptoms, short duration), institution of appropriate empiric antibiotics, based on the patient's age and the organisms and sensitivities commonly present in the community, may discourage a small effusion from developing into a complicated parapneumonic effusion. Whenever possible, a pleural fluid sampling should be performed prior to the initiation of antibiotics.
If a causative organism is identified, antibiotic choice should be guided by the sensitivity pattern of the organism.
Some groups of antibiotics (eg, penicillins, cephalosporins, aztreonam, clindamycin, and ciprofloxacin)[81, 82] exhibit more satisfactory pleural fluid penetration than others (eg, aminoglycosides).[82, 83]
In a hospitalized patient with complicated parapneumonic effusion, antibiotics are commonly administered intravenously while a thoracostomy tube is present and the patient is febrile. No data from randomized trials on an appropriate length of treatment are available, and no data on whether different organisms require different durations are noted. Many centers continue with intravenous antibiotics at least 48 hours after the patient is afebrile and the chest drain is removed. Thereafter, oral antibiotics are commonly continued for 2-4 weeks.
Chest Tube Drainage
Effusions that are enlarging or compromising respiratory function in a febrile, unwell child require drainage. Other risk predictors indicating the need for chest tube placement include frank pus on thoracentesis, a positive pleural fluid Gram stain and culture finding, a pleural fluid pH level of less than 7, a glucose concentration of less than 40 mg/dL, or an LDH level of more than 1000 IU.
Controversy still remains about the optimum chest tube size. Although small-bore tubes (eg, pigtail catheters) are commonly used for free-flowing fluid and large-bore tubes are commonly employed for thick pus, good-quality data that can be used to recommend one size of chest tube over another are lacking. In the absence of evidence that large-bore chest drains confer any advantage, the British Thoracic Society (BTS) guidelines recommend using small-bore chest tubes (including pigtail catheters) whenever possible to minimize patient discomfort. When combined with fibrinolytic therapy, the use of small chest tubes was found to have some advantages over large tubes.
The timing of elective removal of the drain depends on numerous factors, including the amount of fluid draining, the child’s overall clinical condition, the presence of fever, and the radiographic and ultrasonographic appearance of the chest, as well as a fall in acute phase reactants. In most cases, the chest tube may be removed when the pleural drainage becomes minimal (< 10-15 ml/24 h) and the fluid is clear or yellow.
A study by Gilbert et al aimed to review outcomes in patients with hematologic malignancy undergoing indwelling tunneled pleural catheter (IPC) placement. The study reported that IPC placement appears to remain a reasonable clinical option for patients with recurrent pleural effusions related to hematologic malignancy.
Chest Tube Drainage With Instillation of Fibrinolytic Agents
As the effusion becomes fibrinopurulent and subsequently organizes, chest tubes often become ineffective because fibrinous strands and loculations divide the pleural space into compartments. Fibrinolytics instilled into the pleural cavity may facilitate drainage by lysing fibrinous strands and clearing lymphatic pores.
Three fibrinolytic agents have been used: streptokinase, urokinase, and alteplase (or tissue plasminogen activator). Urokinase is no longer available in North America.
In a large double-blind study in adults, Maskell et al reported that use of intrapleural streptokinase did not improve mortality, the rate of surgery, or the length of the hospital stay.
However, numerous published case series have detailed the use of fibrinolytics in children.[87, 88, 89, 90] All indicate improved pleural drainage with these agents and an overall success rate of 80-90% without the need for surgical intervention. Three randomized placebo control trials have been performed in children.
In a multicenter, double-blind, randomized study in children on the use of fibrinolytics for empyema, Thompson and colleagues reported that urokinase resulted in a modest decrease in length of stay (7.39 d vs 9.49 d) and lower treatment failure. The study involved 60 children who were administered either intrapleural urokinase or saline.
In a second study, in which 60 children were randomized to receive either percutaneous chest drain with intrapleural urokinase or video-assisted thoracoscopic surgery (VATS), the authors concluded that urokinase treatment is the better economic option and should be the primary treatment of choice. Treatment costs were significantly lower ($9127 vs $11,379) in the urokinase group than in the VATS patients, while no difference in clinical outcome between the 2 groups was noted. The median duration of hospital stay was 6 days for both groups, with a range of 4-25 days for the urokinase group and 3-16 days for the patients treated with VATS.
In a prospective, randomized trial, St. Peter and colleagues concluded that fibrinolysis should be the first modality selected in children with empyema and that rescue can be done with VATS if necessary. In the study, VATS with decortication was compared with chest tube insertion and administration of tissue plasminogen activator. Eighteen children with empyema were in each group.
The investigators found no difference between the groups with regard to days of hospitalization after intervention, days of oxygen required, days until the children were afebrile, or analgesic requirements. VATS was associated with significantly higher charges. The failure rate for fibrinolysis was 16.6%.
Adverse effects of fibrinolytic agents are usually minor and include discomfort during intrapleural injection, transient blood staining of the drainage fluid, fever, and, rarely, massive bleeding. Rare immediate hypersensitivity reactions have been reported in adults after intrapleural urokinase. Streptokinase that is administered intrapleurally generates a systemic antibody response similar to that found when the drug is given systemically.
Fibrinolytics should not be used in patients with bronchopleural fistula or bubbling chest tube (suggestive of an air leak).
Whether surgery should be the initial treatment of choice or should be reserved for failed medical management is not definitively known. Historically, children with empyema and parapneumonic effusion who failed to improve with antibiotic therapy (with or without drainage) subsequently underwent operative management. Other indications for surgery include persistent sepsis in association with a persistent pleural collection (despite antibiotics, chest tube drainage, and fibrinolytics), complex empyema with significant lung pathology (eg, delayed presentation with a significant peel and trapped lung), and bronchopleural fistula with pyopneumothorax.
Three surgical options are noted for management of children with parapneumonic effusion and empyema:
Open thoracotomy with decortication.
VATS has emerged as the preferred procedure to treat empyema in children and is being increasingly used as primary therapy. VATS is much less invasive than open thoracotomy and is associated with a more favorable outcome.
In a nonrandomized study, VATS use (compared with open thoracotomy with decortication) was associated with shorter duration of analgesia use, postoperative length of hospital stay, time to normothermia, and number of chest tube days.
In a small, prospective, randomized trial, early VATS use (compared with conventional thoracostomy drainage) was associated with few complications and short hospital stays (approximately 7 d).
In a retrospective, 10-year study, Padman et al reported their experience and clinical course of 109 children; 50 patients had VATS, and 59 did not. The use of VATS within 48 hours of admission lead to significant reduction of hospital stay (by 4 days), compared with delayed use of VATS after 48 hours of admission.
A review of 49 pediatric patients with pneumonia complicated by parapneumonic effusion or empyema suggested that patients treated by primary VATS had shorter stay and hospital charges than patient treated by chest tube and antibiotics alone.
Several authors have reported that early VATS is safe and effective and that it shortens hospital stay in the management of empyema in children and adults.[98, 99, 100] However, two prospective studies (mentioned above) comparing early VATS with chest tube and instillation of fibrinolytics[91, 92] suggested that therapy with a chest tube and instillation of fibrinolytics may be more cost effective, may pose less risk of acute clinical deterioration, and should be the first-line therapy for children with empyema.
Mini-thoracotomy achieves debridement and evacuation in a similar manner to VATS but is an open procedure.
Decortication is a major thoracic operation requiring full thoracotomy. It involves an open, posterolateral thoracotomy and removal of all the fibrous tissue from the visceral pleural peel, with all pus being evacuated from the pleural space. It is rarely needed in children with empyema. The BTS guidelines suggest that decortication should be reserved for children with organized empyema, in which a thick, fibrous peel is restricting lung expansion and causing chronic sepsis with fever. [stopped]
Diet and Activity
A dietitian should be consulted early in patients with chylothorax and in those with complicated pleural effusion and empyema, for whom the course may be prolonged.
Chylothorax may respond to a diet with fat supplied as medium-chain triglycerides (MCTs), with a resolution of the chylous effusion at the end of 2 weeks. MCT oil is absorbed directly into the portal circulation and does not contribute to chylomicron formation. Its use may decrease lymph flow by as much as 10-fold. If chylothorax persists, a trial of intravenous (IV) alimentation for 4-5 weeks may be considered.
Children with complicated pleural effusion and empyema may have clinically significant anorexia and increased needs. High-calorie, high-protein foods that appeal to the child should be provided early, and nasogastric feeds should be considered early, particularly in young children.
Pain and chest-tube placement may limit the patient's motility. Analgesia can facilitate cough and clearance of the airway, especially in the presence of an underlying pneumonic process.
For transudative effusions, further outpatient therapy is directed at the underlying etiology of the pleural effusion.
Children with parapneumonic effusion or empyema should be seen for follow up within 4–6 weeks of discharge; the timing depends on the child’s clinical status at discharge. Chest radiography findings are inevitably abnormal at discharge, and a radiograph should be obtained at 4-6 weeks. Complete radiological resolution is usually expected by 3-6 months.[101, 102]
Wang NS. Anatomy of the pleura. Clin Chest Med. 1998 Jun. 19(2):229-40. [Medline].
Agostoni E, Zocchi L. Mechanical coupling and liquid exchanges in the pleural space. Clin Chest Med. 1998 Jun. 19(2):241-60. [Medline].
Alkrinawi S, Chernick V. Pleural infection in children. Semin Respir Infect. 1996 Sep. 11(3):148-54. [Medline].
Hardie W, Bokulic R, Garcia VF, et al. Pneumococcal pleural empyemas in children. Clin Infect Dis. 1996 Jun. 22(6):1057-63. [Medline].
Givan DC, Eigen H. Common pleural effusions in children. Clin Chest Med. 1998 Jun. 19(2):363-71. [Medline].
Alkrinawi S, Chernick V. Pleural fluid in hospitalized pediatric patients. Clin Pediatr (Phila). 1996 Jan. 35(1):5-9. [Medline].
Le Monnier A, Carbonnelle E, Zahar JR, et al. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. Clin Infect Dis. 2006 Apr 15. 42(8):1135-40. [Medline].
Saglani S, Harris KA, Wallis C, Hartley JC. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. Arch Dis Child. 2005 Jan. 90(1):70-3. [Medline].
Buckingham SC, King MD, Miller ML. Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001. Pediatr Infect Dis J. 2003 Jun. 22(6):499-504. [Medline].
Hardie WD, Roberts NE, Reising SF, Christie CD. Complicated parapneumonic effusions in children caused by penicillin- nonsusceptible Streptococcus pneumoniae. Pediatrics. 1998 Mar. 101(3 Pt 1):388-92. [Medline].
Quintero DR, Fan LL. Approach to pleural effusions and empyemas. Paediatr Respir Rev. 2004. 5 Suppl A:S151-2. [Medline].
Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005 Feb. 5(2):83-93. [Medline].
Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J. 2006 Mar. 25(3):250-4. [Medline].
Eltringham G, Kearns A, Freeman R, et al. Culture-negative childhood empyema is usually due to penicillin-sensitive Streptococcus pneumoniae capsular serotype 1. J Clin Microbiol. 2003 Jan. 41(1):521-2. [Medline].
Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003 May 1. 348(18):1737-46. [Medline].
Kaplan SL, Mason EO Jr, Wald ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004 Mar. 113(3 Pt 1):443-9. [Medline].
Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006 Apr 12. 295(14):1668-74. [Medline].
Li ST, Tancredi DJ. Empyema Hospitalizations Increased in US Children Despite Pneumococcal Conjugate Vaccine. Pediatrics. 2009 Nov 30. [Medline].
Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics. 2004 Jun. 113(6):1735-40. [Medline].
Gonzalez BE, Hulten KG, Dishop MK, Lamberth LB, Hammerman WA, Mason EO Jr, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis. 2005 Sep 1. 41(5):583-90. [Medline].
Freij BJ, Kusmiesz H, Nelson JD, McCracken GH Jr. Parapneumonic effusions and empyema in hospitalized children: a retrospective review of 227 cases. Pediatr Infect Dis. 1984 Nov-Dec. 3(6):578-91. [Medline].
Bryant RE, Salmon CJ. Pleural empyema. Clin Infect Dis. 1996 May. 22(5):747-62; quiz 763-4. [Medline].
Cowan MR, Primm PA, Scott SM, Abramo TJ, Wiebe RA. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med. 1994 Apr. 23(4):818-22. [Medline].
Brook I. Microbiology of empyema in children and adolescents. Pediatrics. 1990 May. 85(5):722-6. [Medline].
Merino JM, Carpintero I, Alvarez T, et al. Tuberculous pleural effusion in children. Chest. 1999 Jan. 115(1):26-30. [Medline].
Kim HJ, Lee HJ, Kwon SY, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest. 2006 May. 129(5):1253-8. [Medline].
Cruz AT, Starke JR. Clinical manifestations of tuberculosis in children. Paediatr Respir Rev. 2007 Jun. 8(2):107-17. [Medline].
Panitch HB, Papastamelos C, Schidlow DV. Abnormalities of the pleural space. Taussig LM, Landau LI, eds. Pediatric Respiratory Medicine. 1999. 1178-96.
Sassoon CS, Light RW. Chylothorax and pseudochylothorax. Clin Chest Med. 1985 Mar. 6(1):163-71. [Medline].
Soto-Martinez M, Massie J. Chylothorax: diagnosis and management in children. Paediatr Respir Rev. 2009 Dec. 10(4):199-207. [Medline].
Munoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008 Jan 15. 46(2):174-82. [Medline].
Chonmaitree T, Powell KR. Parapneumonic pleural effusion and empyema in children. Review of a 19-year experience, 1962-1980. Clin Pediatr (Phila). 1983 Jun. 22(6):414-9. [Medline].
Mocelin HT, Fischer GB. Epidemiology, presentation and treatment of pleural effusion. Paediatr Respir Rev. 2002 Dec. 3(4):292-7. [Medline].
Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010 Jan. 125(1):26-33. [Medline].
Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002 Feb 15. 34(4):434-40. [Medline].
Calbo E, Diaz A, Canadell E, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006 Sep. 12(9):867-72. [Medline].
Desrumaux A, Francois P, Pascal C, et al. [Epidemiology and clinical characteristics of childhood parapneumonic empyemas]. Arch Pediatr. 2007 Nov. 14(11):1298-303. [Medline].
Avansino JR, Goldman B, Sawin RS, Flum DR. Primary operative versus nonoperative therapy for pediatric empyema: a meta-analysis. Pediatrics. 2005 Jun. 115(6):1652-9. [Medline].
Meyerovitch J, Shohet I, Rubinstein E. Analysis of thirty-seven cases of pleural empyema. Eur J Clin Microbiol. 1985 Jun. 4(3):337-9. [Medline].
Barbas CS, Cukier A, de Varvalho CR, Barbas Filho JV, Light RW. The relationship between pleural fluid findings and the development of pleural thickening in patients with pleural tuberculosis. Chest. 1991 Nov. 100(5):1264-7. [Medline].
Ampofo K, Byrington C. Management of Parapneumonic Empyema. Pediatr infec Dis J. 2007. 26:445-446.
Lazarus AA, McKay S, Gilbert R. Pleural tuberculosis. Dis Mon. 2007 Jan. 53(1):16-21. [Medline].
Pietsch JB, Whitlock JA, Ford C, Kinney MC. Management of pleural effusions in children with malignant lymphoma. J Pediatr Surg. 1999 Apr. 34(4):635-8. [Medline].
Forbes BA. Critical assessment of gene amplification approaches on the diagnosis of tuberculosis. Immunol Invest. 1997 Jan-Feb. 26(1-2):105-16. [Medline].
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972 Oct. 77(4):507-13. [Medline].
Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest. 1997 Apr. 111(4):970-80. [Medline].
Sahn, SA. Pathogenesis and clinical features of diseases associated with a low pleural fluid glucose. Chretien, J, Bignon, J, Hirsch, A. The Pleura in Health and Disease. New York: Marcel Dekker; 1985. 267-285.
Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med. 1980 Oct. 69(4):507-12. [Medline].
Pettersson T, Klockars M, Hellstrom PE. Chemical and immunological features of pleural effusions: comparison between rheumatoid arthritis and other diseases. Thorax. 1982 May. 37(5):354-61. [Medline]. [Full Text].
Horowitz ML, Schiff M, Samuels J, Russo R, Schnader J. Pneumocystis carinii pleural effusion. Pathogenesis and pleural fluid analysis. Am Rev Respir Dis. 1993 Jul. 148(1):232-4. [Medline].
Sahn SA, Willcox ML, Good JT Jr, Potts DE, Filley GF. Characteristics of normal rabbit pleural fluid: physiologic and biochemical implications. Lung. 1979. 156(1):63-9. [Medline].
Villena Garrido V, Ferrer Sancho J, Hernandez Blasco L, et al. [Diagnosis and treatment of pleural effusion]. Arch Bronconeumol. 2006 Jul. 42(7):349-72. [Medline].
Yam LT. Diagnostic significance of lymphocytes in pleural effusions. Ann Intern Med. 1967 May. 66(5):972-82. [Medline].
Adelman M, Albelda SM, Gottlieb J, Haponik EF. Diagnostic utility of pleural fluid eosinophilia. Am J Med. 1984 Nov. 77(5):915-20. [Medline].
Kalomenidis I, Light RW. Eosinophilic pleural effusions. Curr Opin Pulm Med. 2003 Jul. 9(4):254-60. [Medline].
[Guideline] Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003 May. 58 Suppl 2:ii8-17. [Medline].
Camargos P, Fonseca AC, Amantéa S, Oliveira E, Benfica MD, Chamone C. The role of latex agglutination test for the etiological diagnosis of pleural effusion in children and adolescents. Clin Respir J. 2015 Jul 6. [Medline].
Lee YC, Rogers JT, Rodriguez RM, Miller KD, Light RW. Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest. 2001 Aug. 120(2):356-61. [Medline].
Greco S, Girardi E, Masciangelo R, Capoccetta GB, Saltini C. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis. 2003 Aug. 7(8):777-86. [Medline].
Burgess LJ, Maritz FJ, Le Roux I, Taljaard JJ. Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio. Increased specificity for the diagnosis of tuberculous pleuritis. Chest. 1996 Feb. 109(2):414-9. [Medline].
Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002 Jun 20. 346(25):1971-7. [Medline].
Chaignaud BE, Bonsack TA, Kozakewich HP, Shamberger RC. Pleural effusions in lymphoblastic lymphoma: a diagnostic alternative. J Pediatr Surg. 1998 Sep. 33(9):1355-7. [Medline].
Qureshi NR, Gleeson FV. Imaging of pleural disease. Clin Chest Med. 2006 Jun. 27(2):193-213. [Medline].
Wilson, AG. Pleura and pleural disorders. Armstrong P, Wilson AG, Dee P, et al,. Imaging of diseases of the chest. London: Mosby; 1995. 641-716.
Blackmore CC, Black WC, Dallas RV, Crow HC. Pleural fluid volume estimation: a chest radiograph prediction rule. Acad Radiol. 1996 Feb. 3(2):103-9. [Medline].
Moskowitz H, Platt RT, Schachar R, Mellins H. Roentgen visualization of minute pleural effusion. An experimental study to determine the minimum amount of pleural fluid visible on a radiograph. Radiology. 1973 Oct. 109(1):33-5. [Medline].
Kelbel C, Borner N, Schadmand S, et al. [Diagnosis of pleural effusions and atelectases: sonography and radiology compared]. Rofo. 1991 Feb. 154(2):159-63. [Medline].
Hirsch JH, Rogers JV, Mack LA. Real-time sonography of pleural opacities. AJR Am J Roentgenol. 1981 Feb. 136(2):297-301. [Medline].
Lipscomb DJ, Flower CD, Hadfield JW. Ultrasound of the pleura: an assessment of its clinical value. Clin Radiol. 1981 May. 32(3):289-90. [Medline].
Wolek R, Mason BJ, Reeser P, Zins JH. Pleural fluid: accuracy of computed tomography in differentiating exudates from transudates. Conn Med. 1998 May. 62(5):259-65. [Medline].
Aquino SL, Webb WR, Gushiken BJ. Pleural exudates and transudates: diagnosis with contrast-enhanced CT. Radiology. 1994 Sep. 192(3):803-8. [Medline].
Arenas-Jimenez J, Alonso-Charterina S, Sanchez-Paya J, et al. Evaluation of CT findings for diagnosis of pleural effusions. Eur Radiol. 2000. 10(4):681-90. [Medline].
Donnelly LF, Klosterman LA. CT appearance of parapneumonic effusions in children: findings are not specific for empyema. AJR Am J Roentgenol. 1997 Jul. 169(1):179-82. [Medline].
Jaffe A, Calder AD, Owens CM, Stanojevic S, Sonnappa S. Role of routine computed tomography in paediatric pleural empyema. Thorax. 2008 Oct. 63(10):897-902. [Medline].
Calder A, Owens CM. Imaging of parapneumonic pleural effusions and empyema in children. Pediatr Radiol. 2009 Jun. 39(6):527-37. [Medline].
Donnelly LF, Klosterman LA. The yield of CT of children who have complicated pneumonia and noncontributory chest radiography. AJR Am J Roentgenol. 1998 Jun. 170(6):1627-31. [Medline].
Calder A, Owens CM. Imaging of parapneumonic pleural effusions and empyema in children. Pediatr Radiol. 2009 Jun. 39(6):527-37. [Medline].
Jaffe A, Balfour-Lynn IM. Management of empyema in children. Pediatr Pulmonol. 2005 Aug. 40(2):148-56. [Medline].
Light RW, Rodriguez RM. Management of parapneumonic effusions. Clin Chest Med. 1998 Jun. 19(2):373-82. [Medline].
Teixeira LR, Sasse SA, Villarino MA, Nguyen T, Mulligan ME, Light RW. Antibiotic levels in empyemic pleural fluid. Chest. 2000 Jun. 117(6):1734-9. [Medline].
Thys JP, Vanderhoeft P, Herchuelz A, Bergmann P, Yourassowsky E. Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas. Chest. 1988 Mar. 93(3):530-2. [Medline].
Thomson AH, Hull J, Kumar MR, et al. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax. 2002 Apr. 57(4):343-7. [Medline].
Gilbert CR, Lee HJ, Skalski JH, Maldonado F, Wahidi M, Choi PJ, et al. The Use of Indwelling Tunneled Pleural Catheters for Recurrent Pleural Effusions in Patients With Hematologic Malignancies: A Multicenter Study. Chest. 2015 Sep 1. 148 (3):752-8. [Medline].
Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005 Mar 3. 352(9):865-74. [Medline].
Barbato A, Panizzolo C, Monciotti C, et al. Use of urokinase in childhood pleural empyema. Pediatr Pulmonol. 2003 Jan. 35(1):50-5. [Medline].
Kilic N, Celebi S, Gurpinar A, et al. Management of thoracic empyema in children. Pediatr Surg Int. 2002 Jan. 18(1):21-3. [Medline].
Kornecki A, Sivan Y. Treatment of loculated pleural effusion with intrapleural urokinase in children. J Pediatr Surg. 1997 Oct. 32(10):1473-5. [Medline].
Krishnan S, Amin N, Dozor AJ, Stringel G. Urokinase in the management of complicated parapneumonic effusions in children. Chest. 1997 Dec. 112(6):1579-83. [Medline].
Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med. 2006 Jul 15. 174(2):221-7. [Medline].
St Peter SD, Tsao K, Spilde TL, et al. Thoracoscopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. J Pediatr Surg. 2009 Jan. 44(1):106-11; discussion 111. [Medline].
Laisaar T, Pullerits T. Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions. Chest. 2003 Feb. 123(2):432-5. [Medline].
Subramaniam R, Joseph VT, Tan GM, Goh A, Chay OM. Experience with video-assisted thoracoscopic surgery in the management of complicated pneumonia in children. J Pediatr Surg. 2001 Feb. 36(2):316-9. [Medline].
Kurt BA, Winterhalter KM, Connors RH, Betz BW, Winters JW. Therapy of parapneumonic effusions in children: video-assisted thoracoscopic surgery versus conventional thoracostomy drainage. Pediatrics. 2006 Sep. 118(3):e547-53. [Medline].
Padman R, King KA, Iqbal S, Wolfson PJ. Parapneumonic effusion and empyema in children: retrospective review of the duPont experience. Clin Pediatr (Phila). 2007 Jul. 46(6):518-22. [Medline].
Aziz A, Healey JM, Qureshi F, et al. Comparative analysis of chest tube thoracostomy and video-assisted thoracoscopic surgery in empyema and parapneumonic effusion associated with pneumonia in children. Surg Infect (Larchmt). 2008 Jun. 9(3):317-23. [Medline].
Kim BY, Oh BS, Jang WC, et al. Video-assisted thoracoscopic decortication for management of postpneumonic pleural empyema. Am J Surg. 2004 Sep. 188(3):321-4. [Medline].
Petrakis IE, Kogerakis NE, Drositis IE, et al. Video-assisted thoracoscopic surgery for thoracic empyema: primarily, or after fibrinolytic therapy failure?. Am J Surg. 2004 Apr. 187(4):471-4. [Medline].
Gates RL, Caniano DA, Hayes JR, Arca MJ. Does VATS provide optimal treatment of empyema in children? A systematic review. J Pediatr Surg. 2004 Mar. 39(3):381-6. [Medline].
Chan PW, Crawford O, Wallis C, Dinwiddie R. Treatment of pleural empyema. J Paediatr Child Health. 2000 Aug. 36(4):375-7. [Medline].
McLaughlin FJ, Goldmann DA, Rosenbaum DM, et al. Empyema in children: clinical course and long-term follow-up. Pediatrics. 1984 May. 73(5):587-93. [Medline].
Walker CA, Shirk MB, Tschampel MM, Visconti JA. Intrapleural alteplase in a patient with complicated pleural effusion. Ann Pharmacother. 2003 Mar. 37(3):376-9. [Medline].
Wells RG, Havens PL. Intrapleural fibrinolysis for parapneumonic effusion and empyema in children. Radiology. 2003 Aug. 228(2):370-8. [Medline].